We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Just two weeks after hauling in a $31 million series A funding round to form a new subsidiary, Boston-based IFM Therapeutics is laying out a case for the unit’s primary drug target.....